[1]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
　ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]

点击复制

新型降糖药物在心力衰竭中的应用前()

分享到：

参考文献/References:

[1]Seferovi?/span> PM,Petrie MC,Filippatos GS,et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2018,20(5):853-872.

[2]Pavlovi?A,Polovina M,Risti?A,et al. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction[J]. Eur J Prev Cardiol,2019,26(1):72-82.

[3]Lawson CA,Jones PW,Teece L,et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population[J]. JACC Heart Fail,2018,6(1):18-26.

[4]Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur J Heart Fail,2016,18(8):891-975.

[5]?inar J,?ahelová A. SAVOR-TIMI 53—saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. Vnitr Lek,2013,59(11):1003.

[6] Scirica BM, Braunwald E, Raz I, et al.Heart failure,saxagliptin,and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial[J]. Circulation,2014,130(18):1579-1588.

[7]Green JB,Bethel MA,Armstrong PW,et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2015,373(3):232-242.

[8]Zannad F,Cannon CP,Cushman WC,et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre,randomised,double-blind trial[J]. Lancet,2015,385(9982):2067-2076.

[9]Rosenstock J,Perkovic V,Johansen OE,et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial[J]. JAMA,2019,321(1)-69-79.

[10]Packer M. worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms,clinical risks,and potential influence of concomitant antidiabetic medications[J]. JACC Heart Fail,2018,6(6):445-451.

[11]Anderluh M,Kocic G,Tomovic K,et al. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors[J]. Pharmacol Ther,2016,167:100-107.

[12]吉家钗,陈娟,符策岗.利拉鲁肽通过促进自噬减轻去氧肾上腺素诱导的原代大鼠心肌肥厚[J].心血管病学进展,2019,40(7):1067-1072.

[13]Maack C,Lehrke M,Backs J,et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology[J]. Eur Heart J,2018,39(48):4243-4254.

[14]Husain M,Birkenfeld AL,Donsmark M,et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2019,381(9):841-851.

[15]Pfeffer MA,Claggett B,Diaz R. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med,2015,373(23):2247-2257.

[16]Holman RR,Bethel MA,Mentz RJ,et al. Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2017,377(13):1228.

[17]Marso SP,Daniels GH,Brown-Frandsen K,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-322.

[18]Marso SP,Bain SC,Consoli A,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844.

[19]Pieber TR,Bode B,Mertens A,et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre,open-label,randomised,phase 3a trial[J]. Lancet Diabetes Endocrinol,2019,7(7):528-539.

[20]Velez M,Peterson EL,Wells K,et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes[J]. J Card Fail,2015,21(1):2-8.

[21]Jorsal A,Kistorp C,Holmager P,et al. Effect of liraglutide,a glucagon-like peptide-1 analogue,on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre,double-blind,randomised,placebo-controlled trial[J]. Eur J Heart Fail,2017,19(1):69-77.

[22] Hernandez AF, Green JB, Janmohamed S, et al.Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind,randomised placebo-controlled trial[J]. Lancet,2018,329(10157):1519-1529.

[23]Gerstein HC,Colhoun HM,Dagenais GR,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,randomised placebo-controlled trial[J]. Lancet,2019,394(10193):121-130.

[24]Ferrannini E,Baldi S,Frascerra S,et al. Renal handling of ketones in response to sodium–glucose cotransporter 2 inhibition in patients with type 2 diabetes[J]. Diabetes Care,2017,40(6):771-776.

[25]Joubert M,Jagu B,Montaigne D,et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model[J]. Diabetes,2017,66(4):1030-1040.

[26]Mudaliar S,Alloju S,Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis[J]. Diabetes Care,2016,39(7):1115-1122.

[27]Kappel BA,Lehrke M,Schütt K,et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease[J]. Circulation,2017,136(10):969-972.

[28]Baartscheer A,Schumacher CA,Wüst RC,et al. Empagliflozin decreases myocardial cytoplasmic Na+through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J]. Diabetologia,2017,60(3):568-573.

[29]Bertero E,Maack C. Calcium signaling and reactive oxygen species in mitochondria[J]. Circ Res,2018,122(10):1460-1478.

[30]Cherney DZ,Perkins BA,Soleymanlou N,et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J]. Circulation,2014,129(5):587-597.

[31]Chilton R,Tikkanen I,Cannon CP,et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab,2015,17(12):1180-1193.

[32]Verma S,Garg A,Yan AT,et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?[J]. Diabetes Care,2016,39(12):e212-e213.

[33]Rosenstein R,Hough A. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Eng J Med,2016,374(11):1092-1094.

[34]Fitchett D,Zinman B,Wanner C,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME? trial[J]. Eur Heart J,2016,37(19):1526-1534.

[35]Butler J,Hamo CE,Filippatos G,et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors[J]. Eur J Heart Fail,2017,19(11):1390-1400.

[36]Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.

[37]Figtree GA,Radholm K,Barrett TD,et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus[J]. Circulation,2019,139(22):2591-2593.

[38]Wiviott SD,Raz I,Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes reply[J]. N Engl J Med,2019,380(19):1881-1882.

[39]McMurray J,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995-2008.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]李少杰 苏康康 王震 谷剑 陈淑霞.钠-葡萄糖共转运蛋白2抑制剂对心律失常影响的研究进展[J].心血管病学进展,2023,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.014]
　LI S haojie,SU K angkang,WANG Z hen,et al.Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Arrhythmias[J].Advances in Cardiovascular Diseases,2023,(6):251.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.014]